Multiplex PCR VS Culture, Study to assess the Clinical response and Cost effectiveness

Multiplex PCR for Syndromic testing VS Conventional Standard of care testing A Prospective Study to assess the Clinical response and Cost effectiveness - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/10/076043

Enrollment

Registered

2024-10-29

Start date

Unknown

Completion date

Unknown

Last updated

2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B965- Pseudomonas (aeruginosa) (mallei)(pseudomallei) as the cause of diseases classified elsewhere

Interventions

Intervention1: MULTIPLEX POLYMERASE CHAIN REACTION: IT WILL BE DONE FOR BLOOD AND TRACHEAL SECRETIONS ONLY ONE TIME ON ADMISSION TO ICU. THE EMPIRICAL ANTIBIOTICS WILL BE MODIFIED ACCORDING TO ITS REP

Eligibility

Inclusion criteria

Inclusion criteria: All adults (=15 years and =90 years) ICU patients with suspected BSI or LRTI who are started on empirical antibiotics.

Exclusion criteria

Exclusion criteria: Age 65 years, Patients with UTI, meningitis and septic foci other than BSI and LRTI. (excluded on the basis of history, examination and routine investigations)

Design outcomes

Primary

Measure	Time frame
To see patient’s clinical response (to change in treatment with multiplex PCR reports) by change in composite organ failure score (SOFA score) at the end of 1 weekTimepoint: Day 7	—

Secondary

Measure	Time frame
To see patients clinical response by: Total ICU days Mortality at day 7 & 30 To study the decrease in the empirical antibiotic days & total antibiotic costs. Timepoint: DAY 7 & 30	—

Countries

India

Contacts

Public ContactDr Ritu Singh

Indira Gandhi Institute of Medical Sciences Patna

ritusingh140@gmail.com8127395753

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026